Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14


Immunotherapy for prostate cancer: False promises or true hope?

Rekoske BT, McNeel DG.

Cancer. 2016 Dec 1;122(23):3598-3607. doi: 10.1002/cncr.30250.


Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination.

Colston JM, Bolinger B, Cottingham MG, Gilbert S, Klenerman P.

J Immunol. 2016 Apr 15;196(8):3354-63. doi: 10.4049/jimmunol.1502687.


DNA vaccination for prostate cancer: key concepts and considerations.

Cole G, McCaffrey J, Ali AA, McCarthy HO.

Cancer Nanotechnol. 2015;6(1):2.


Sipuleucel-T: immunotherapy for advanced prostate cancer.

Olson BM, McNeel DG.

Open Access J Urol. 2011 May 3;3:49-60. doi: 10.2147/OAJU.S13069. Review.


Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?

Karan D.

Immunotherapy. 2013 Sep;5(9):907-10. doi: 10.2217/imt.13.83. Review. No abstract available.


Prostate cancer vaccines: Update on clinical development.

Geary SM, Salem AK.

Oncoimmunology. 2013 May 1;2(5):e24523.


Proposed mechanisms of action for prostate cancer vaccines.

Geary SM, Lemke CD, Lubaroff DM, Salem AK.

Nat Rev Urol. 2013 Mar;10(3):149-60. doi: 10.1038/nrurol.2013.8. Review.


Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations.

Lemke CD, Geary SM, Joshi VB, Salem AK.

Biomaterials. 2013 Mar;34(10):2524-9. doi: 10.1016/j.biomaterials.2012.12.030.


A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.


CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD.

J Gene Med. 2012 Jun;14(6):416-27. doi: 10.1002/jgm.1648. Review.


PSA regulates androgen receptor expression in prostate cancer cells.

Saxena P, Trerotola M, Wang T, Li J, Sayeed A, Vanoudenhove J, Adams DS, Fitzgerald TJ, Altieri DC, Languino LR.

Prostate. 2012 May 15;72(7):769-76. doi: 10.1002/pros.21482.


Update on prostate cancer vaccines.

Drake CG.

Cancer J. 2011 Sep-Oct;17(5):294-9. doi: 10.1097/PPO.0b013e3182325e78. Review.


Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.

Lemke CD, Graham JB, Geary SM, Zamba G, Lubaroff DM, Salem AK.

Mol Pharm. 2011 Oct 3;8(5):1652-61. doi: 10.1021/mp100464y.

Supplemental Content

Support Center